UNICHEM LABORATORIES LTD.

Unichem Laboratories Ltd announced the extension of the exercise period for vested options under its Employee Stock Option Scheme 2018. The Nomination and Remuneration Committee (NRC) approved the extension via circular resolution on September 11, 2026. This affects the first and second tranches of vested options, with the exercise period now extended to March 31, 2027, from the previous date of September 30, 2026. The first tranche comprises 250,000 options vesting on July 1, 2024, and the second tranche includes 125,000 options vesting on May 1, 2025. All other terms and conditions of the granted options remain unchanged.

Unichem Laboratories Ltd has responded to an exchange query regarding a significant increase in its securities' trading volume. The company stated that the surge is purely market-driven and that it has no further comments to offer. Unichem Laboratories affirmed its commitment to making timely disclosures of all material events and information as per SEBI (LODR) Regulations, 2015, and will continue to comply with its disclosure obligations.

Unichem Laboratories Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated profit after tax (PAT) of ₹41.47 Crores, a significant increase from the previous year's corresponding quarter. Total income for the quarter stood at ₹648.23 Crores. The Board of Directors approved these financial statements, which were also accompanied by the auditors' limited review report. The results will be available on the company's website and stock exchange portals.

Unichem Laboratories' consolidated (primary) results show a clear year-on-year turnaround: Q1 FY27 revenue rose 20.1% YoY to ₹632.62 Cr (from ₹526.60 Cr) and net profit swung to ₹41.47 Cr from a ₹10.47 Cr loss in Q1 FY26. Sequentially the print was also strong — revenue up 10.0% and PAT up ~280% over Q4 FY26's ₹575.12 Cr / ₹10.91 Cr — though that base included a ₹12.36 Cr one-off employee-benefit provision (New Labour Codes) that is absent this quarter, so part of the QoQ jump is a clean-base effect rather than fresh momentum. The margin story is the real driver: consolidated NPM expanded to 6.4% of total income from -2.0% a year ago and 1.8% last quarter, and pre-exceptional PBT margin swung to +7.7% of revenue from -1.7% YoY. The bridge is cost of materials consumed falling to 30.0% of revenue (₹190.02 Cr) from 41.3% (₹217.48 Cr) a year ago, even as revenue grew — a meaningful raw-material/mix improvement — partly offset by other expenses rising 12.6% YoY to ₹170.78 Cr. Employee costs were roughly flat (₹103.31 Cr vs ₹107.42 Cr YoY). The basis matters here: standalone (India) revenue actually declined 4.7% YoY to ₹366.27 Cr, and standalone PAT of ₹5.53 Cr was entirely a function of ₹16.72 Cr other income — on core operations alone, standalone expenses (₹375.61 Cr) exceeded revenue. The consolidated beat is thus concentrated overseas: auditors note the US subsidiary and UK-based Niche Generics together booked ₹470.28 Cr of revenue and ₹12.39 Cr of PAT this quarter, reviewed by other (non-principal) auditors. We have no formal management guidance on record and no prior concall read to check this print against, and no solid Street consensus for this specific quarter turned up in search — so vsGuidance and vsStreet are both marked unknown rather than assumed. Company events this quarter were largely procedural (AGM notice, board meeting notice) aside from a partial GSTR TRAN-1 credit allowance from CGST appellate authorities on 29th July 2026, whose P&L impact, if any, isn't quantified in this filing. Going forward, the print sets up three things to track: whether the standalone (domestic) business returns to organic profitability without leaning on other income, whether the outsized overseas contribution (₹470.28 Cr) is a sustainable run-rate or a one-quarter spike, and whether the raw-material cost improvement (30.0% of revenue) holds as input costs and product mix normalize.

Unichem Laboratories Ltd has received a partial decision from the Additional Commissioner, CGST (Appeals), Dehradun, regarding its appeal for GSTR TRAN 1 credit. The appeal was filed against an order disallowing a credit of ₹73,02,757/-. The appellate authority has now allowed a portion of the credit, raising a demand of ₹10,59,354/- plus interest. The company stated that this will have no material impact on its financial or operational activities and plans to take appropriate steps, including a potential further appeal.

Unichem Laboratories Ltd announced that its Board of Directors will convene on Tuesday, August 11, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results, both consolidated and standalone, for the quarter that concluded on June 30, 2026. This meeting is a routine procedural step for the company to finalize and disclose its quarterly financial performance.

Unichem Laboratories Ltd has responded to a stock exchange query regarding a significant price movement in its securities. The company stated that it has consistently complied with SEBI's disclosure requirements and is unaware of any undisclosed material information that could have caused the price surge. Unichem attributes the price increase to market-driven factors and confirms its commitment to ongoing compliance with listing regulations.

Unichem Laboratories Ltd. has informed shareholders, particularly those without registered email addresses, about accessing the Annual Report for FY 2025-26. In compliance with SEBI regulations, the company has sent letters providing a web-link to the report. The 63rd Annual General Meeting is scheduled for August 11, 2026. The communication also serves as a reminder for shareholders holding physical securities to update KYC details and dematerialize shares as per recent SEBI mandates, to ensure eligibility for payments like dividends. Shareholders are encouraged to update their email addresses for continued access to important information and to support green initiatives.

Unichem Laboratories Ltd has issued letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for FY 2025-26. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The 63rd Annual General Meeting is scheduled for August 11, 2026, via video conferencing. The company also reminds shareholders to update KYC details and dematerialize physical securities as per recent SEBI mandates, highlighting the electronic payment requirement for non-compliant folios from April 1, 2024.

Unichem Laboratories Ltd has announced its 63rd Annual General Meeting (AGM) will be held on Tuesday, August 11, 2026, at 3:30 p.m. IST via Video Conference/Other Audio-Visual Means. The meeting will cover ordinary business, including the adoption of audited standalone and consolidated financial statements for the financial year 2025-26. Key special business includes the re-appointment of Mr. Pabitrakumar Bhattacharyya as Managing Director & CEO for a further three-year term and the ratification of remuneration for the Cost Auditors, Kishore Bhatia & Associates, for the financial year ending March 31, 2027.